A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Warfarin in Atrial Fibrillation, sponsored by Bayer. Completed at 165 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-04-20.
Sponsored by Bayer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.
Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 14th largest by enrollment, is the only one that started in 2007, is one of 16 in phase 3, and was the 2nd registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 22+
China National Center for Cardiovascular Diseases · Sites in China
Ages 70+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–89
Xijing Hospital · Sites in China
Ages 18+
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19–99
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 17 · Phase 4 19
First in 2004; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,280 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 150 across the 45 interventional studies. Of the 26 that completed or were terminated, 7 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 45 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
64 studies in Atrial Fibrillation by Bayer: 1 open now, 1 under way, none of them phase 3. Of 61 finished, 4 (7%) have results posted.
Among the 64 studies in Atrial Fibrillation by Bayer, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2007, is one of 4 in phase 3, and was the 1st registered.
Bayer’s Atrial Fibrillation studies by the year they started, since 2004.
3 of the studies testing rivaroxaban in Atrial Fibrillation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06108414China National Center for Cardiovascular DiseasesLow-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation | 2026-12-31 |
| NCT05487950Assistance Publique - Hôpitaux de ParisRivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk | 2027-04-05 |
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 45 studies testing rivaroxaban in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bayer’s 64 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).
Within the US 'Johnson \& Johnson Pharmaceutical Research \& Development, L.L.C.' is sponsor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period
Drug: Rivaroxaban (Xarelto, BAY59-7939) · Drug: Warfarin placebo
Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period
Drug: Warfarin · Drug: Rivaroxaban placebo
Participants orally administered rivaroxaban 15 mg OD (CrCL \[creatinine clearance\] \>= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
Participants orally administered a warfarin potassium tablet (INR \[international normalized ratio\] target was 1.6-2.6 for patients \>70 years and 2.0-3.0 for patients \<70 years)
Participants orally administered a rivaroxaban placebo tablet
Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding
Major bleeding: clinically overt bleeding (COB) associated with a fall in hemoglobin ≥2 g/dL, leading to transfusion ≥2 units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Non-major clinically relevant bleeding: COB that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.
Time frame: Up to 2 days after the last dose
Event Rate of the Composite Endpoint of Adjudicated Stroke and Non-central Nervous System (CNS) Systemic Embolism
This is the principal efficacy endpoint. Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded.
Time frame: Up to 2 days after the last dose
Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, and Vascular Death
Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Any death that was not clearly non-vascular.
Time frame: Up to 2 days after the last dose
Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, Myocardial Infarction, and Vascular Death
Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Myocardial infarction: assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for ≥2 leads, or autopsy confirmation. Any death that was not clearly non-vascular.
Time frame: Up to 2 days after the last dose
Event Rate of Stroke
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Stroke included hemorrhagic (Stroke with local collections of intraparenchymal blood. Subarachnoid hemorrhage, subdural hemorrhage, and epidural hemorrhage were excluded.), ischemic infarction (Stroke without focal collection of intracranial blood) and unknown (No imaging data and anatomic findings were available.).
Time frame: Up to 2 days after the last dose
Event Rate of Non-CNS Systemic Embolism
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-CNS systemic embolism was abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (such as trauma, atherosclerosis, and instrumentation). Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded from this category.
Time frame: Up to 2 days after the last dose
Event Rate of Myocardial Infarction
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Myocardial infarction was assessed based on either cardiac bio-markers (troponin I, troponin T, or creatine kinase-muscle and brain subunit isozyme), new abnormal Q waves appeared on ECG for 2 or more leads, or autopsy confirmation.
Time frame: Up to 2 days after the last dose
Event Rate of Vascular Death
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Any death that was not clearly non-vascular (e.g., deaths due to spontaneous bleeding, myocardial infarction, stroke, cardiac failure, and arrhythmia)
Time frame: Up to 2 days after the last dose
Event Rate of Stroke With Serious Residual Disability
All events were adjudicated and confirmed by a central independent committee blinded to treatment. A stroke was considered disabling if the participant's modified Rankin score was between 3 and 5, inclusive.
Time frame: Up to 2 days after the last dose
Event Rate of All-cause Death
All events were adjudicated and confirmed by a central independent committee blinded to treatment. All-cause death included vascular death and non-vascular death.
Time frame: Up to 2 days after the last dose
Event Rate of Adjudicated Major Bleeding
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Major bleeding was clinically overt bleeding associated with a fall in hemoglobin of 2 g/dL or higher, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death.
Time frame: Up to 2 days after the last dose
Event Rate Adjudicated Non-major Clinically Relevant Bleeding
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-major clinically relevant bleeding was clinically overt bleeding that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.
Time frame: Up to 2 days after the last dose
The first participant entered the study on 08 Jun 2007, and the last participant completed the study on 19 Jan 2010. The study was conducted at 167 centers in Japan. 164 study centers enrolled at least 1 participant.
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Started | 640 | 640 |
| Started treatment | 639 | 639 |
| Completed | 480 | 468 |
| Not completed | 160 | 172 |
| Withdrew: Adverse event | 73 | 70 |
| Withdrew: Withdrawal by subject | 26 | 35 |
| Withdrew: Death | 8 | 3 |
| Withdrew: Physician decision | 4 | 13 |
| Withdrew: Lost to follow-up | 4 | 1 |
| Withdrew: Protocol violation | 9 | 9 |
| Withdrew: Clinical endpoint reached | 18 | 28 |
| Withdrew: Non-compliant with study medication | 3 | 1 |
| Withdrew: Protocol driven decision point | 12 | 8 |
| Withdrew: Site closed by investigator | 1 | 2 |
| Withdrew: Site closed by sponsor | 1 | 1 |
| Withdrew: Drop out before treatment start | 1 | 1 |
| Milestone | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Started | 639 | 639 |
| Entered fu and valid for safety | 628 | 630 |
| Completed | 610 | 616 |
| Not completed | 29 | 23 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 13 | 12 |
| Withdrew: Lost to follow-up | 6 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 5 | 5 |
| Withdrew: Clinical endpoint reached | 3 | 2 |
Major bleeding: clinically overt bleeding (COB) associated with a fall in hemoglobin ≥2 g/dL, leading to transfusion ≥2 units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Non-major clinically relevant bleeding: COB that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of the Composite Endpoint of Adjudicated Major Bleeding or Adjudicated Non-major Clinically Relevant Bleeding | 18.04 | 16.42 |
This is the principal efficacy endpoint. Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded.
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of the Composite Endpoint of Adjudicated Stroke and Non-central Nervous System (CNS) Systemic Embolism | 1.26 | 2.61 |
Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Any death that was not clearly non-vascular.
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, and Vascular Death | 1.83 | 2.85 |
Stroke included hemorrhagic, ischemic infarction and unknown. Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded. Myocardial infarction: assessed based on either cardiac biomarkers, new abnormal Q waves appeared on electrocardiogram for ≥2 leads, or autopsy confirmation. Any death that was not clearly non-vascular.
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of the Composite Endpoint of Adjudicated Stroke, Non-CNS Systemic Embolism, Myocardial Infarction, and Vascular Death | 2.18 | 2.97 |
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Stroke included hemorrhagic (Stroke with local collections of intraparenchymal blood. Subarachnoid hemorrhage, subdural hemorrhage, and epidural hemorrhage were excluded.), ischemic infarction (Stroke without focal collection of intracranial blood) and unknown (No imaging data and anatomic findings were available.).
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of Stroke | 1.15 | 2.49 |
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-CNS systemic embolism was abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms (such as trauma, atherosclerosis, and instrumentation). Arterial emboli in the following areas were "non-CNS systemic embolism": peripheral arterial in the upper and lower extremities, renal, mesenteric, splenic, hepatic, ocular/retinal and others. Pulmonary embolism or myocardial infarction was excluded from this category.
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of Non-CNS Systemic Embolism | 0.11 | 0.12 |
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Myocardial infarction was assessed based on either cardiac bio-markers (troponin I, troponin T, or creatine kinase-muscle and brain subunit isozyme), new abnormal Q waves appeared on ECG for 2 or more leads, or autopsy confirmation.
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of Myocardial Infarction | 0.34 | 0.12 |
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Any death that was not clearly non-vascular (e.g., deaths due to spontaneous bleeding, myocardial infarction, stroke, cardiac failure, and arrhythmia)
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of Vascular Death | 0.69 | 0.24 |
All events were adjudicated and confirmed by a central independent committee blinded to treatment. A stroke was considered disabling if the participant's modified Rankin score was between 3 and 5, inclusive.
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of Stroke With Serious Residual Disability | 0.57 | 1.19 |
All events were adjudicated and confirmed by a central independent committee blinded to treatment. All-cause death included vascular death and non-vascular death.
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of All-cause Death | 0.80 | 0.59 |
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Major bleeding was clinically overt bleeding associated with a fall in hemoglobin of 2 g/dL or higher, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death.
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate of Adjudicated Major Bleeding | 3.00 | 3.59 |
All events were adjudicated and confirmed by a central independent committee blinded to treatment. Non-major clinically relevant bleeding was clinically overt bleeding that does not meet the definition of major bleeding, but requires medical intervention or unscheduled contact with the physician, (temporary) discontinuation of the study treatment, discomfort to the subject such as pain, or impairment of activities of daily life.
| Events per 100 patient-years | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin |
|---|---|---|
| Event Rate Adjudicated Non-major Clinically Relevant Bleeding | 15.42 | 12.99 |
Collected over Reporting Group (RG) 1 + 2: Safety data collected start with the first dose of study drug up to 2 days after the last dose; Reporting Group (RG) 3 + 4: Safety data collected from last dose plus 2 days to end of trial.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RG1: Rivaroxaban Double-blind (DB) Period | — | 151/639 (23.6%) | 474/639 (74.2%) |
| RG2: Warfarin DB Period | — | 155/639 (24.3%) | 470/639 (73.6%) |
| RG3: Rivaroxaban Follow-up (FU) Period | — | 50/628 (8%) | 73/628 (11.6%) |
| RG4: Warfarin FU Period | — | 37/630 (5.9%) | 61/630 (9.7%) |
| Event | RG1: Rivaroxaban Double-blind (DB) Period | RG2: Warfarin DB Period | RG3: Rivaroxaban Follow-up (FU) Period | RG4: Warfarin FU Period |
|---|---|---|---|---|
| Ischaemic strokeNervous system disorders | 9/639 | 18/639 | 10/628 | 4/630 |
| PneumoniaInfections and infestations | 14/639 | 10/639 | 3/628 | 3/630 |
| Cardiac failureCardiac disorders | 12/639 | 11/639 | 3/628 | 4/630 |
| CataractEye disorders | 9/639 | 7/639 | 0/628 | 0/630 |
| Colonic polypGastrointestinal disorders | 5/639 | 9/639 | 0/628 | 1/630 |
| Atrial fibrillationCardiac disorders | 4/639 | 2/639 | 0/628 | 1/630 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 0/639 | 4/639 | 0/628 | 0/630 |
| IleusGastrointestinal disorders | 0/639 | 4/639 | 0/628 | 0/630 |
| Sudden deathGeneral disorders | 4/639 | 2/639 | 3/628 | 0/630 |
| Spinal compression fractureInjury, poisoning and procedural complications | 4/639 | 2/639 | 0/628 | 0/630 |
| Event | RG1: Rivaroxaban Double-blind (DB) Period | RG2: Warfarin DB Period | RG3: Rivaroxaban Follow-up (FU) Period | RG4: Warfarin FU Period |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 206/639 | 232/639 | 16/628 | 15/630 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 102/639 | 59/639 | 6/628 | 8/630 |
| Haemorrhage subcutaneousSkin and subcutaneous tissue disorders | 67/639 | 79/639 | 9/628 | 6/630 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 55/639 | 74/639 | 3/628 | 1/630 |
| ContusionInjury, poisoning and procedural complications | 58/639 | 56/639 | 4/628 | 4/630 |
| DiarrhoeaGastrointestinal disorders | 57/639 | 40/639 | 3/628 | 6/630 |
| Back painMusculoskeletal and connective tissue disorders | 50/639 | 56/639 | 5/628 | 7/630 |
| Gingival bleedingGastrointestinal disorders | 54/639 | 31/639 | 1/628 | 2/630 |
| Diabetes mellitusMetabolism and nutrition disorders | 43/639 | 31/639 | 0/628 | 1/630 |
| EczemaSkin and subcutaneous tissue disorders | 37/639 | 43/639 | 2/628 | 1/630 |
| Age, Continuous(Years) | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin | Total |
|---|---|---|---|
| Mean | 71.0 ± 8.3 | 71.2 ± 7.9 | 71.1 ± 8.1 |
| Sex: Female, Male(Participants) | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin | Total |
|---|---|---|---|
| Female | 110 | 140 | 250 |
| Male | 530 | 500 | 1030 |
| CL(CR) [creatinine clearance](Participants) | Rivaroxaban (Xarelto, BAY59-7939) | Warfarin | Total |
|---|---|---|---|
| <50 mL/min | 141 | 143 | 284 |
| 50 to <80 mL/min | 329 | 329 | 658 |
| ≥80 mL/min | 170 | 168 | 338 |
Showing the first 100 of 165 sites. Choose a country and city above to see the rest.
The record gives a start of Jun 2007, a primary completion of Dec 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2012, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban